NCT06939270View on ClinicalTrials.gov

CD73/AXL Targeted HypoSti.CAR-T Cells in CD73/AXL Positive Advanced/Metastatic Solid Tumors

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

May 1, 2025

Primary Completion Date

May 1, 2027

Study Completion Date

May 1, 2028

Conditions
Solid Tumor
Interventions
BIOLOGICAL

CD73/AXL.HypoSti.CAR-T cells

Dose escalation: Dose1 (1×10\^6 cells/kg) , Dose 2(3×10\^6 cells/kg) ,Dose 3 (1×10\^7cells/kg); Dose expansion: RP2D.

DRUG

Albumin-Bound Paclitaxel

Administered intravenously at dose of 100-200mg/m2 on day -5 .

DRUG

Cyclophosphamide

Administered intravenously at a total dose of 15-30mg/kg on day -3 and day -2 .

DRUG

Fludarabine

Administered intravenously at dose of 30mg/m2/d on day -3 and day -2.

Trial Locations (1)

Unknown

Biotherapeutic Department, Chinese PLA General Hospital, Beijing

All Listed Sponsors
collaborator

Fudan University

OTHER

lead

Chinese PLA General Hospital

OTHER

NCT06939270 - CD73/AXL Targeted HypoSti.CAR-T Cells in CD73/AXL Positive Advanced/Metastatic Solid Tumors | Biotech Hunter | Biotech Hunter